Enveric Biosciences, Inc.
ENVB
$1.64
$0.042.19%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 25.55% | -17.11% | 25.62% | -15.30% | 30.74% |
| Total Depreciation and Amortization | -5.82% | -2.23% | 1.00% | -50.62% | -1.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -59.84% | 362.61% | -71.74% | 7.84% | -78.34% |
| Change in Net Operating Assets | -868.13% | 133.37% | -178.37% | 179.93% | -154.59% |
| Cash from Operations | -26.44% | 13.98% | -9.78% | 20.97% | -82.36% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -6.91% | -10.14% | 566.31% | -89.91% | 819.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -6.91% | -10.14% | 566.31% | -89.91% | 860.06% |
| Foreign Exchange rate Adjustments | -196.79% | 262.50% | -166.67% | 7.69% | 82.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -74.86% | 1.33% | 162.84% | -170.35% | 335.83% |